Search details
1.
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med
; 390(12): 1080-1091, 2024 Mar 21.
Article
in English
| MEDLINE | ID: mdl-38507751
2.
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
N Engl J Med
; 388(18): 1645-1656, 2023 May 04.
Article
in English
| MEDLINE | ID: mdl-37133584
3.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Lancet
; 403(10437): 1649-1659, 2024 Apr 27.
Article
in English
| MEDLINE | ID: mdl-38582092
4.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 401(10390): 1773-1785, 2023 05 27.
Article
in English
| MEDLINE | ID: mdl-37086745
5.
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
N Engl J Med
; 385(25): 2336-2347, 2021 12 16.
Article
in English
| MEDLINE | ID: mdl-34914339
6.
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
Breast Cancer Res Treat
; 2024 Mar 08.
Article
in English
| MEDLINE | ID: mdl-38456970
7.
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Eur J Nucl Med Mol Imaging
; 2024 Apr 08.
Article
in English
| MEDLINE | ID: mdl-38587643
8.
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Oncologist
; 28(1): 23-32, 2023 01 18.
Article
in English
| MEDLINE | ID: mdl-36239405
9.
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.
Breast Cancer Res Treat
; 201(2): 151-159, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37338729
10.
Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer.
Int J Mol Sci
; 24(10)2023 May 09.
Article
in English
| MEDLINE | ID: mdl-37239834
11.
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Lancet Oncol
; 22(4): 489-498, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33794206
12.
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Lancet Oncol
; 22(2): 212-222, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33460574
13.
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Lancet Oncol
; 22(6): 858-871, 2021 06.
Article
in English
| MEDLINE | ID: mdl-34019819
14.
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
Breast Cancer Res Treat
; 184(2): 469-479, 2020 Nov.
Article
in English
| MEDLINE | ID: mdl-32876911
15.
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
Breast Cancer Res Treat
; 174(3): 693-701, 2019 Apr.
Article
in English
| MEDLINE | ID: mdl-30607629
16.
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Breast Cancer Res Treat
; 177(1): 115-125, 2019 Aug.
Article
in English
| MEDLINE | ID: mdl-31152327
17.
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study.
Invest New Drugs
; 37(1): 98-108, 2019 02.
Article
in English
| MEDLINE | ID: mdl-29948356
18.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(12): 1688-1700, 2017 12.
Article
in English
| MEDLINE | ID: mdl-29146401
19.
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Lancet
; 388(10063): 2997-3005, 2016 12 17.
Article
in English
| MEDLINE | ID: mdl-27908454
20.
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Breast Cancer Res Treat
; 156(1): 81-9, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26909792